Home › Targets › PDE9A
Radioligand therapy target profile

PDE9A: IHC Expression in Cancer and Radioligand Target Profile

phosphodiesterase 9A · Ensembl ENSG00000160191 · Data updated 2026-11-01

PDE9A, phosphodiesterase 9A, is a cell-surface protein. In Human Protein Atlas immunohistochemistry, PDE9A staining is highest in lung cancer (80% of samples positive), bladder cancer (88% of samples positive) and neuroendocrine tumors (75% of samples positive). Clinical status: FDA-approved drug (any modality).

Is PDE9A the right target for your program? Rank it against 15,000 targets on dosimetry, internalization and clinical risk.

Analyze PDE9A free
LocalizationCell-Surface
Top cancer (IHC)Lung Cancer
InternalizationNot assessed
Clinical stageFDA-approved drug (any modality)
Active trialsSee ClinicalTrials.gov
Cancer association (Open Targets)0.28

Is PDE9A a good radioligand therapy target?

Scored against the six criteria that decide whether a protein can become a radioligand therapy:

PDE9A IHC staining by cancer type

Protein expression of PDE9A across 20 cancer types from Human Protein Atlas immunohistochemistry. The score is a weighted staining intensity from 0 to 1; "% positive" is the share of patient samples with detectable staining.

Cancer typeIHC scoreLevel% positive
Lung Cancer0.53High80%
Bladder Cancer0.50Medium88%
Neuroendocrine Tumors0.50Medium75%
Melanoma0.48Medium82%
Endometrial Cancer0.48Medium73%
Ovarian Cancer0.47Medium75%
Colorectal Cancer0.44Medium83%
Glioma0.39Medium58%
Pancreatic Cancer0.36Medium73%
Cervical Cancer0.36Medium58%
Breast Cancer0.30Medium55%
Liver Cancer0.30Medium50%
Kidney Cancer0.19Low33%
Gastric Cancer0.17Low30%
Skin Cancer0.17Low25%
Prostate Cancer0.10Low20%
Thyroid Cancer0.08Low25%

Not detected by IHC in: head and neck cancer, lymphoma, testicular cancer.

Is PDE9A internalized?

Nuclens has not yet extracted internalization evidence for PDE9A. Internalization matters for radioligands because an internalizing receptor traps the radionuclide inside the tumor cell. Run a free analysis to pull the latest literature.

PDE9A clinical trials

FDA-approved drug (any modality). Nuclens hasn't indexed trials for PDE9A yet. Search ClinicalTrials.gov for PDE9A trials.

PDE9A normal tissue expression

Normal-tissue expression in dose-limiting organs (kidney, liver, bone marrow, salivary glands) drives radioligand dosimetry risk. Nuclens is re-validating its normal-tissue values, so they are not shown here yet. See PDE9A in the Human Protein Atlas tissue atlas, and read how normal-tissue expression predicts radioligand dosimetry risk.

PDE9A gene essentiality (DepMap)

CRISPR knockout effect across 1251 cancer cell lines: 0.06 (not essential). Radioligands kill by radiation, not by blocking the target, so essentiality matters less than for inhibitors. A non-essential target can still be an excellent radioligand target.

Related lung cancer radioligand targets

EGFR · HER3 (ERBB3) · c-MET (MET) · EPCAM · CEA (CEACAM5) · STEAP2 · B7-H3 (CD276) · Mesothelin (MSLN)

See all radioligand therapy targets in lung cancer.

See how PDE9A ranks against 15,000 targets for your indication.

Analyze PDE9A free

Data sources

Subcellular localization: UniProt via Open Targets (CC BY 4.0 / CC0). Tumor immunohistochemistry: Human Protein Atlas (CC BY-SA 4.0). Clinical trials: ClinicalTrials.gov (public domain). Gene essentiality: DepMap (CC BY 4.0). Internalization and shedding: AI-extracted from PubMed abstracts, so verify against the cited papers before relying on them. Nuclens is a first-pass triage layer, not a substitute for wet-lab validation or clinical dosimetry. Derived expression data on this page is shared under CC BY-SA 4.0.

Is PDE9A the right target for your program? · 5 free analyses, no card Analyze PDE9A free